Drug Trial Radar · NCT04361032
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia
Last checked: Nov 19, 2026Latest source record: Aug 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
260
Planned (sponsor's estimate)
Start
Sep 4, 2020
Primary completion
Sep 4, 2020
Study completion Oct 4, 2020
Sponsor
- Lead sponsor
- Abderrahmane Mami HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eshmoun Clinical Research Center; Datametrix
- First posted
- Apr 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Conditions
- COVID19
- Intensive Care Unit
Interventions
Tocilizumab InjectionDrug
Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
DeferoxamineDrug
Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- the mortality rateTime frame: 90 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana
Aryanah, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.